Black Diamond Therapeutics Swings to $22.4M Net Income in FY25, Extends Cash Runway; Silevertinib Data Positive
Summary
Black Diamond Therapeutics reported a significant financial turnaround for the full year 2025, achieving a net income of $22.4 million, a substantial improvement from a $69.7 million net loss in 2024. The company also bolstered its cash position to $128.7 million, extending its cash runway into the second half of 2028, significantly de-risking its financial outlook. Furthermore, the corporate update included positive initial Phase 2 data for silevertinib in NSCLC, demonstrating a 60% Objective Response Rate and 86% CNS ORR. This combination of strong financial performance and promising clinical progress provides a significant boost to the company's investment thesis. Traders should monitor upcoming presentations of updated silevertinib clinical data and the initiation of its randomized Phase 2 trial in GBM during the second quarter of 2026 for further catalysts.
At the time of this announcement, BDTX was trading at $2.14 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $124.8M. The 52-week trading range was $1.20 to $4.94. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.